Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 24 studies | 43% ± 24% | |
B cell | 16 studies | 26% ± 9% | |
memory B cell | 15 studies | 31% ± 10% | |
regulatory T cell | 10 studies | 25% ± 6% | |
myeloid cell | 9 studies | 36% ± 12% | |
alveolar macrophage | 8 studies | 70% ± 24% | |
monocyte | 7 studies | 31% ± 14% | |
conventional dendritic cell | 7 studies | 33% ± 18% | |
non-classical monocyte | 6 studies | 23% ± 8% | |
fibroblast | 5 studies | 18% ± 2% | |
naive B cell | 4 studies | 28% ± 2% | |
endothelial cell | 4 studies | 29% ± 11% | |
mononuclear phagocyte | 3 studies | 37% ± 2% | |
exhausted T cell | 3 studies | 27% ± 4% | |
epithelial cell of proximal tubule | 3 studies | 21% ± 3% | |
dendritic cell | 3 studies | 31% ± 17% | |
mast cell | 3 studies | 18% ± 2% | |
gamma-delta T cell | 3 studies | 23% ± 5% | |
T cell | 3 studies | 18% ± 2% | |
plasmacytoid dendritic cell | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 8318.08 | 577 / 578 | 97% | 101.71 | 1119 / 1155 |
breast | 89% | 1348.93 | 409 / 459 | 94% | 94.92 | 1056 / 1118 |
stomach | 88% | 2238.06 | 316 / 359 | 88% | 54.01 | 253 / 286 |
kidney | 96% | 2732.65 | 85 / 89 | 81% | 104.38 | 726 / 901 |
uterus | 90% | 1001.75 | 153 / 170 | 83% | 75.19 | 380 / 459 |
ovary | 97% | 1173.91 | 175 / 180 | 75% | 34.82 | 324 / 430 |
intestine | 89% | 1412.14 | 859 / 966 | 82% | 47.04 | 433 / 527 |
skin | 73% | 1265.68 | 1315 / 1809 | 98% | 234.50 | 461 / 472 |
esophagus | 72% | 882.16 | 1037 / 1445 | 89% | 47.17 | 163 / 183 |
bladder | 76% | 541.38 | 16 / 21 | 84% | 56.85 | 425 / 504 |
pancreas | 70% | 524.77 | 229 / 328 | 90% | 70.79 | 160 / 178 |
prostate | 91% | 1164.02 | 222 / 245 | 65% | 37.84 | 328 / 502 |
liver | 67% | 590.23 | 152 / 226 | 63% | 39.90 | 255 / 406 |
thymus | 38% | 244.28 | 250 / 653 | 79% | 41.98 | 475 / 605 |
eye | 0% | 0 | 0 / 0 | 100% | 379.13 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 213.94 | 29 / 29 |
spleen | 100% | 3398.63 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 103.53 | 44 / 45 |
peripheral blood | 97% | 1638.77 | 903 / 929 | 0% | 0 | 0 / 0 |
adipose | 92% | 1745.21 | 1106 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 60% | 404.22 | 154 / 258 | 11% | 4.48 | 26 / 230 |
blood vessel | 28% | 609.55 | 374 / 1335 | 0% | 0 | 0 / 0 |
heart | 8% | 43.27 | 70 / 861 | 0% | 0 | 0 / 0 |
brain | 1% | 11.12 | 38 / 2642 | 6% | 2.90 | 42 / 705 |
muscle | 2% | 10.47 | 19 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0060349 | Biological process | bone morphogenesis |
GO_0034097 | Biological process | response to cytokine |
GO_0042554 | Biological process | superoxide anion generation |
GO_0032695 | Biological process | negative regulation of interleukin-12 production |
GO_0045019 | Biological process | negative regulation of nitric oxide biosynthetic process |
GO_0032691 | Biological process | negative regulation of interleukin-1 beta production |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0006809 | Biological process | nitric oxide biosynthetic process |
GO_0032929 | Biological process | negative regulation of superoxide anion generation |
GO_0016311 | Biological process | dephosphorylation |
GO_0045453 | Biological process | bone resorption |
GO_0010936 | Biological process | negative regulation of macrophage cytokine production |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0016020 | Cellular component | membrane |
GO_0005764 | Cellular component | lysosome |
GO_0005829 | Cellular component | cytosol |
GO_0003993 | Molecular function | acid phosphatase activity |
GO_0008198 | Molecular function | ferrous iron binding |
GO_0008199 | Molecular function | ferric iron binding |
Gene name | ACP5 |
Protein name | Tartrate-resistant acid phosphatase type 5 (EC 3.1.3.2) Tartrate-resistant acid phosphatase type 5 Acid phosphatase 5, tartrate resistant Tartrate-resistant acid phosphatase type 5 (TR-AP) (EC 3.1.3.2) (Tartrate-resistant acid ATPase) (TrATPase) (Type 5 acid phosphatase) |
Synonyms | |
Description | FUNCTION: Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias. |
Accessions | ENST00000695811.1 ENST00000695817.1 ENST00000695810.1 K7EIP0 ENST00000649386.2 ENST00000695809.1 K7ESF2 ENST00000695820.1 A0A8Q3SI79 ENST00000695821.1 A0A3B3IS75 A0A8Q3WKT0 ENST00000648477.1 A0A8Q3WKS0 ENST00000695813.1 A0A8Q3WLB6 ENST00000589792.5 ENST00000412435.7 ENST00000588625.2 ENST00000649386.1 ENST00000590832.1 ENST00000695791.1 ENST00000695814.1 A0A8Q3WKS1 ENST00000695818.1 ENST00000592828.6 ENST00000218758.10 ENST00000589792.6 P13686 ENST00000592828.7 K7EJD9 ENST00000591319.2 ENST00000590832.2 ENST00000591319.1 ENST00000592659.2 ENST00000695815.1 |